Recent News

• 06.11.2025 - Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
• 06.11.2025 - Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
• 06.05.2025 - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.05.2025 - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.04.2025 - 2025 Jefferies Global Healthcare Conference
• 05.21.2025 - 2025 RBC Capital Markets Global Healthcare Conference
• 05.15.2025 - Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
• 05.15.2025 - Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
• 05.14.2025 - Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
• 05.14.2025 - Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

Recent Filings

• 06.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2025 - 144 Report of proposed sale of securities
• 06.04.2025 - 144 Report of proposed sale of securities
• 05.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.08.2025 - EX-99.1 EX-99.1